Strategies to Promote Access to Medicines of Interest in Public Health: Structured Review of the Literature

Authors

  • Mónica Ledezma Morales University of Antioquia https://orcid.org/0000-0003-4307-1282
  • Pedro Amariles University of Antioquia
  • Claudia Marcela Vargas Peláez IFARMA Foundation
  • Francisco Augusto Rossi Buenaventura IFARMA Foundation

DOI:

https://doi.org/10.17533/udea.rfnsp.v38n1e332273

Keywords:

accessibility to health services, health policy, medicine, intellectual property, medicine price

Abstract

Objective: To identify strategies aimed at promoting access to high-cost or patent-protected medicines of interest in public health, possibly applicable to the Colombian context. Methodology: structured review in PubMed/Medline, using the MeSH terms: “health services accessibility”, “pharmaceutical preparations”, “policy”, with filters for articles published in English and Spanish, between 2012 and 2017. Studies with
information on strategies or policies that favored access to high-cost or patent-protected drugs of interest in public health were included. The strategies identified were grouped according to the five dimensions of access to health care and medicines defined by the World Health Organization: availability, affordability,
accessibility, acceptability and quality. Results: 62 articles were identified, of which 18 were included, and 5 additional references were considered. 30 strategies were recognised, distributed and classified according to the dimensions of access: availability and affordability, 15; accessibility, 6; acceptability, 6; quality, 2; cross-cutting strategy, 1. Conclusions: Key strategies were identified to favor access to high-cost or patent-
protected medicines of interest in public health, including centralized price negotiations; public financial support for national research, development and production of generic medicines; the application of the flexibilities of the agreement on “Aspects of intellectual property rights related to trade” and the implementation of care programs.
|Abstract
= 2668 veces | PDF (ESPAÑOL (ESPAÑA))
= 1140 veces| | HTML (ESPAÑOL (ESPAÑA))
= 94 veces|

Downloads

Download data is not yet available.

Author Biographies

Mónica Ledezma Morales, University of Antioquia

Master in Research and Rational Use of Medicines, pharmaceutical chemistry. Doctoral student in Pharmaceutical and Food Sciences, University of Antioquia, Colombia.

Pedro Amariles, University of Antioquia

Doctor of Pharmacy, Pharmaceutical Chemist, University of Antioquia, Colombia.

Claudia Marcela Vargas Peláez, IFARMA Foundation

Doctor of Pharmacy, Pharmaceutical Chemistry, IFARMA Foundation, Colombia.

Francisco Augusto Rossi Buenaventura, IFARMA Foundation

Epidemiologist, doctor, IFARMA Foundation, Colombia.

References

World Health Organization. wha28.66 Sustancias profilácticas y terapéuticas. 28.a Asamblea Mundial de la Salud [internet]; 1975 [citado 2017 jun. 20]. Disponible en: http://apps.who.int/ medicinedocs/documents/s21447es/s21447es.pdf.

Bigdeli M, Jacobs B, Tomson G, et al. Access to medicines from a health system perspective. Health Policy Plan. 2013;28(7):692- 704. doi: https://doi.org/10.1093/heapol/czs108.

Giedion U, Bitrán RA, Tristao I, editores. Planes de beneficios en salud de América Latina. Una comparación regional. Washington: Inter-American Development Bank, Social Protection and Health Division; 2014.

United Nations. Final Report. The United Nations SecretaryGeneral’s High-Level Panel on Access to Medicines [internet]. 2016 [citado 2017 may. 6]. Disponible en: http://www. unsgaccessmeds.org/final-report/.

World Health Organization. Monitoring Health for the sdgs. Sustainable Development Goals [internet]. Geneva: World Health Organization [internet]; 2017 [citado 2018 ene. 30]. (World Health Statistics). Disponible en: http://apps.who.int/iris/ bitstream/10665/255336/1/9789241565486-eng.pdf.

World Health Organization. The World Medicines Situation Report [internet]. Geneva: World Health Organization; 2011 [citado 2018 ene. 30]. Disponible en: http://www.who.int/ medicines/areas/policy/world_medicines_situation/en/.

Gómez SM, Olaya P, Díaz FJ. Resistencia a los medicamentos antirretrovirales en pacientes que reciben tratamiento para vihsida en Colombia. Infectio. 2010;14(4):248-57. doi: https://doi. org/10.1016/S0123-9392(10)70118-1.

Management Sciences for Health. mds-3: Managing Access to Medicines and Health Technologies [internet]. Arlington, va: Management Sciences for Healt [internet]; 2012 [citado 2017 jun. 20]. Disponible en: http://apps.who.int/medicinedocs/ documents/s19577en/s19577en.pdf.

Colombia, Consejo Nacional de Política Económica y Social. Política Farmacéutica Nacional. (2012 ago. 30). Disponible en: https://www. minsalud.gov.co/Documentos%20y%20Publicaciones/Politica%20 Farmac%C3%A9utica%20Nacional.pdf.

Colombia, Ministerio de Salud y Protección Social, Dirección de Regulación de Beneficios, Costos y Tarifas del Aseguramiento en Salud. Comparación entre el listado de medicamentos esenciales de la oms número 19 y el listado de medicamentos cubiertos por el Plan de Beneficios en Salud con cargo a la Unidad de Pago por Capitación definido mediante Resolución 5592 de 2015 [internet]; 2016. Disponible en: https://www.minsalud.gov.co/sites/rid/ Lists/BibliotecaDigital/RIDE/VP/RBC/Informe-medicamentosesenciales-oms-listado-medicamentos-pbsupc.pdf.

Machado Alba JE, Moncada Escobar JC. Evolución del consumo de medicamentos de alto costo en Colombia. Rev Panam Salud Pública. 2012;31(4):283-9. doi: https://doi.org/10.1590/S1020- 49892012000400003.

Reveiz L, Chapman E, Torres R, et al. Litigios por derecho a la salud en tres países de América Latina: revisión sistemática de la literatura. Rev Panam Salud Pública. 2013;33(3):213-22. doi: https://doi.org/10.1590/S1020-49892013000300008.

World Health Organization. Declaración de Doha [internet]. 2001 [citado 2017 feb. 13]. Disponible en: www.wto.org/ spanish/res_s/booksp_s/ddec_s.pdf.

Gentile I, Maraolo AE, Niola M, et al. Limiting the access to direct-acting antivirals against hcv: An ethical dilemma. Expert Rev Gastroenterol Hepatol. 2016;10(11):1227-34. doi: https:// doi.org/10.1080/17474124.2016.1234375.

Pashkov VM, Golovanova IA, Olefir AA. The impact of the legal regime of intellectual property protection in the pharmaceutical market. Wiad Lek. 2016;69(3):582-6. Disponible en: https:// www.ncbi.nlm.nih.gov/pubmed/?term=27717949.

Wirtz VJ, Kaplan WA, Kwan GF, et al. Access to medications for cardiovascular diseases in low- and middle-income countries. Circulation. 2016;133(21):2076-85. doi: https://doi.org/10.1161/ CIRCULATIONAHA.115.008722.

Kishore SP, Kolappa K, Jarvis JD, et al. Overcoming obstacles to enable access to medicines for noncommunicable diseases in poor countries. Health Aff (Millwood). 2015;34(9):1569-77. doi: https://doi.org/10.1377/hlthaff.2015.0375.

Trooskin SB, Reynolds H, Kostman JR. Access to costly new hepatitis C drugs: Medicine, money, and advocacy. Clin Infect Dis. 2015;61(12):1825-30. doi: https://doi.org/10.1093/cid/ civ677.

Hutchinson SJ, Dillon JF, Fox R, et al. Expansion of hcv treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland’s experience. Int J Drug Policy. 2015;26(11):1041-9. doi: https://doi.org/10.1016/j.drugpo.2015.05.019.

Hoffman SJ, So K, Galappati P, et al. Assessing 15 proposals for promoting innovation and access to medicines globally. Ann Glob Health. 2014;80(6):432-43. doi: http://doi.org/10.1016/j. aogh.2015.02.004.

Dylst P, Vulto A, Simoens S. Societal value of generic medicines beyond cost-saving through reduced prices. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):701-11. doi: https:// doi.org/10.1586/14737167.2015.1017565.

Pinheiro E dos S, Brüning K, Macedo MF, et al. Production of antiretroviral drugs in middle- and low-income countries. Antivir Ther. 2014;19(Suppl 3):49-55. doi: https://doi.org/10.3851/ IMP2900.

Pascual F. Intellectual property rights, market competition and access to affordable antiretrovirals. Antivir Ther. 2014;19(Suppl 3):57-67. doi: https://doi.org/10.3851/IMP2901.

Hill JE. Changes to intellectual property policy in South Africa: Putting a stop to evergreening? Expert Opin Ther Pat. 2014;24(8):839-43. doi: https://doi.org/10.1517/13543776.201 4.931376.

Lemoine M, Thursz M. Hepatitis C, a global issue: Access to care and new therapeutic and preventive approaches in resourceconstrained areas. Semin Liver Dis. 2014;34(01):089-97. doi: https://doi.org/10.1055/s-0034-1371082.

Kredo T, Ford N, Adeniyi FB, et al. Decentralising hiv treatment in lower- and middle-income countries. En: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [internet]. Chichester, uk: John Wiley & Sons, Ltd; 2013 [citado 2017 may. 18]. Disponible en: http://doi.wiley. com/10.1002/14651858.CD009987.pub2.

Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduct J. 2013;10:7. doi: https://doi. org/10.1186/1477-7517-10-7.

The Lancet Oncology. Is India ready to lead the battle for fair access to medicines? Lancet Oncol. 2013;14(6):437. doi: https:// doi.org/10.1016/S1470-2045(13)70197-9.

Hogerzeil HV, Liberman J, Wirtz VJ, et al. Promotion of access to essential medicines for non-communicable diseases: Practical Rev. Fac. Nac. Salud Pública Vol. 38 N.º 1 enero - abril 2020 14 Universidad de Antioquia implications of the un political declaration. The Lancet. 2013;381(9867):680-9. doi: https://doi.org/10.1016/S0140- 6736(12)62128-X.

Valverde AM, Reed SD, Schulman KA. Proposed “grantand-access” program with price caps could stimulate development of drugs for very rare diseases. Health Aff (Millwood). 2012;31(11):2528-35. doi: https://doi.org/10.1377/ hlthaff.2012.0235.

Westley E, Schwarz EB. Emergency contraception: Global challenges, new opportunities. Contraception. 2012;85(5):429- 31. doi: https://doi.org/10.1016/j.contraception.2012.01.012.

Chaves GC, Hasenclever L, Osorio-de-Castro CG, et al. Strategies for price reduction of hiv medicines under a monopoly situation in Brazil. Rev Saúde Pública [internet]; 2015 [citado 2017 ago. 25]; 49(0):1-10. Disponible en: http://www.scielo.br/scielo. php?script=sci_arttext&pid=S0034-89102015000100309&lng= en&tlng=en.

Congreso de la República de Colombia. Ley 1753 de 2015. Plan Nacional de Desarrollo (2015 jun. 9).

World Health Organization (who). Essential medicines [internet]; s. f. [citado 2017 mar. 7]. Disponible en: http://www. who.int/medicines/services/essmedicines_def/en/.

Colombia, Ministerio de Salud y Protección Social. Resolución 1692, por la cual se establecen los criterios para la compra centralizada, distribución y suministro de medicamentos para la hepatitis C crónica y el seguimiento a los pacientes diagnosticados con dicha patología y se dictan otras disposiciones (2017 may. 23).

Colombia, Ministerio de Salud y Protección Social. Medicamentos contra hepatitis C, ahora 80 % más baratos [internet]; 2017 [citado 2018 feb. 13]. Disponible en: https:// www.minsalud.gov.co/Paginas/Medicamentos-contra-hepatitisC-ahora-80-mas-baratos.aspx.

Consultor Salud. Así quedaría control de precio de medicamentos [internet]; 2013 [citado 2018 abr. 23]. Disponible en: http:// www.consultorsalud.com/asi-quedaria-control-de-precio-demedicamentos.

World Health Organization. Acuerdo sobre los aspectos de los derechos de propiedad intelectual relacionados con el comercio [internet]; 1995 [citado 2017 feb. 14]. Disponible en: https:// www.wto.org/SPANISH/DOCS_S/legal_s/27-trips.pdf.

Comisión de la Comunidad Andina. Decisión 486 de 2000 (2000 sep. 14).

Colombia, Ministerio de Salud y Protección Social. Resolución 2475, por medio de la cual se adelanta una declaratoria de existencia de razones de interés público (2016 jun. 14).

Colombia, Ministerio de Salud y Protección Social, Dirección de Prestación de Servicios y Atención Primaria. Línea base de telemedicina en municipios priorizados – Colombia. Resultados generales [internet]; 2015 [citado 2018 may. 4]. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/ BibliotecaDigital/RIDE/VS/PSA/linea-base-telemedicinamunicpios-priorizados.pdf.

Colombia, Ministerio de Salud y Protección Social. Política de Atención Integral en Salud. Bogotá, Colombia; 2016. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/ BibliotecaDigital/RIDE/DE/modelo-pais-2016.pdf.

Downloads

Published

2020-02-13

How to Cite

1.
Ledezma Morales M, Amariles P, Vargas Peláez CM, Rossi Buenaventura FA. Strategies to Promote Access to Medicines of Interest in Public Health: Structured Review of the Literature. Rev. Fac. Nac. Salud Pública [Internet]. 2020 Feb. 13 [cited 2025 Dec. 6];38(1):1-14. Available from: https://revistas.udea.edu.co/index.php/fnsp/article/view/332273

Issue

Vol. 38 No. 1 (2020): Enero-Abril

Section

Servicios de salud

License

Copyright (c) 2020 Facultad Nacional de Salud Pública

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The contents of the articles are the responsibility of the authors

The editorial committee has editorial independence from the National School of Public Health "Héctor Abad Gómez" of the University of Antioquia.

The editorial committee is not responsible for aspects related to copying, plagiarism or fraud that may appear in the articles published in it.

When you are going to reproduce and disclose photographs or personal data in printed or digital format, informed consent is required. Therefore, this requirement is required of the author at the time of receipt of the manuscript.

Authors are responsible for obtaining the necessary permissions to reproduce any material protected by reproduction rights.

The authors preserve the moral rights and assign the economic rights that will correspond to the University of Antioquia, to publish it, distribute electronic copies, include them in indexing services, directories or national and international databases in Open Access, under the Creative Commons Attribution license -Not Commercial-Share Equal 4.0 International Commercial (CC BY-NC-SA) which allows others to distribute, remix, retouch, and create from the work in a non-commercial way, as long as the respective credit and license are granted. new creations under the same conditions.

The authors will sign the declaration of transfer of economic rights to the University of Antioquia, after the acceptance of the manuscript.

The editorial committee reserves the right to reject the articles whose authors do not offer satisfactory explanations about the contribution of each author, to meet the criteria of authorship in the submission letter. All authors must meet the four criteria of authorship according to ICMJE: "a) .- That there is a substantial contribution to the conception or design of the article or to the acquisition, analysis or interpretation of the data. b) That they have participated in the design of the research work or in the critical review of its intellectual content. c) .- That has been intervened in the approval of the final version that will be published.d). That they have the capacity to respond to all aspects of the article in order to ensure that issues related to the accuracy or integrity of any part of the work are adequately investigated and resolved. "

Crossref
Scopus
Google Scholar
Europe PMC